Paxlovid loses luster in people who aren't at high risk from Covid-19, Pfizer study finds

The antiviral medication Paxlovid appears to be most effective in people whose age or underlying health puts them at high risk for becoming severely ill with Covid-19, but it appears

Related Keywords

Massachusetts ,United States ,Boston ,Albert Bourla ,Cassandra Pierre ,Michael Charness ,Ruanne Barnabus ,Pfizer ,Boston Veterans Affairs Healthcare System ,Boston Medical Center ,Warnermedia Company ,Drug Administration ,Shell ,Cable News Network Inc ,Veterans Affairs Healthcare ,Boston Medical ,Massachusetts General Hospital ,News Network ,Cnn ,Usiness And Industry Sectors ,Business ,Conomy And Trade ,Companies ,Coronavirus ,Iseases And Disorders ,Ealth And Medical ,Health Care ,Infectious Diseases ,Ife Forms ,Icroscopic Life ,Pfizer Inc ,Pharmaceutical Industry ,Pharmaceuticals ,Harmaceuticals And Prescription Drugs ,Respiratory Diseases ,Viruses ,Paxlovid ,Patient ,Medicine ,Hospital ,Harmacology ,Medication ,